Please login to the form below

Not currently logged in
Email:
Password:

rucaparib

This page shows the latest rucaparib news and features for those working in and with pharma, biotech and healthcare.

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for

Latest news

More from news
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics